Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02486744 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population
A Phase 1 study, sponsored by Youngstown State University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02486744: Clinical Trial Phase 1 study, sponsored by Youngstown State University.
NCT02486744 is a Phase 1 study that was terminated before completion, run by Youngstown State University. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02486744, a Phase 1 study, was terminated before completion, sponsored by Youngstown State University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This will be a prospective observational study of Acthar Gel in Non-Diabetic Hemodialysis \[NDHD\] patients receiving dialysis for ≤ 2 years. The project will aimed at providing proof-of-concept data that 80 U two times \[2x\] week Acthar for 6 months is a safe and effective therapy for NDHD. Effectiveness of lower dose 40 U 2X week will also be determined. Therefore the study will be a repeated measures design (Time x condition) comparison of improvement in renal function, nutritional status, quality of life and physical performance resulting from Acthar therapy.
Primary Outcome
Maintain or improve renal function \[Creatinine clearance and Proteinuria\] by ≥ 20% , as measured by eGFR or 24 hour urine study.
Interventions
- DRUG Acthar Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Why NCT02486744 stopped before completion
NCT02486744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Acthar Gel is the first listed.
NCT02486744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02486744 about?
NCT02486744 is a clinical study titled "Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population". This will be a prospective observational study of Acthar Gel in Non-Diabetic Hemodialysis \[NDHD\] patients receiving dialysis for ≤ 2 years. The project will aimed at providing proof-of-concept data that 80 U two times \[2x\] week Acthar for 6 months is a safe and effective therapy for NDHD. Effect...
What is the current status of trial NCT02486744?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-03. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02486744?
The interventions under investigation include: Acthar Gel (DRUG).
Who is sponsoring clinical trial NCT02486744?
This trial is sponsored by Youngstown State University, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02486744's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia